MADISON, N.J., Feb. 1, 2011 /PRNewswire/ — Quest Diagnostics
DGX) today announced the pricing of the previously announced
secondary public offering of 15,377,600 shares of Quest Diagnostics
common stock held by its largest stockholder, SB Holdings Capital
Inc., an affiliate of GlaxoSmithKline plc (“GSK”) at a price to the
public of $56.25.
Quest Diagnostics has not sold any shares of common stock in the
offering and will not receive any of the proceeds from the sale of
shares in the offering.
Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are
joint bookrunners for the offering.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities. A
registration statement relating to these securities has been filed
with the Securities and Exchange Commission and is effective.
A written prospectus for this offering meeting the
requirements of Section 10 of the Securities Act of 1933 (other
than a free writing prospectus as defined in Securities Act Rule
405) may be obtained from Deutsche Bank Securities Inc., 100 Plaza
One, Jersey City, N.J. 07311 or by calling 1-800-503-4611, or J.P.
Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717 or by calling
About Quest Diagnostics
Quest Diagnostics is the world’s leading provider of diagnostic
testing, information and services that patients and doctors need to
make better healthcare decisions. The company offers the broadest
access to diagnostic testing services through its network of
laboratories and patient service centers, and provides interpretive
consultation through its extensive medical and scientific staff.
Quest Diagnostics is a pioneer in developing innovative diagnostic
tests and advanced healthcare information technology solutions